The five-year pact puts CRT in charge of discovering drugs that affect protein assembly and taking them through phase 1.
Scientists at the University of Michigan Comprehensive Cancer Center believe they've discovered a novel gene that can be inhibited with antisense…
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
Teva's restructuring plan will include the closure or divestiture of R&D facilities, as well as a "thorough review" of its R&D programs.
Kyn Therapeutics has debuted after almost two years of gestation at Atlas Venture with three immuno-metabolism platforms and $49 million in funding.
The 144 patients who received Ampion in the latest trial outperformed tthe control cohort in terms of the responder criteria,
Relay Therapeutics has bumped up its cash with a strong second funding round as it eyes clinical work on its next-gen cancer drug development.
Bristol-Myers Squibb has licensed a phase 1 immuno-oncology drug from Japan’s Ono in a $40 million upfront pact.
AMRC will provide preclinical support to startups working out of an incubator overseen by the foundation.
Two new research insights might help make checkpoint inhibition an effective option for many more lung cancer patients.
The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA.